75 related articles for article (PubMed ID: 11783236)
1. [Cell differentiation and apoptosis of tumor cells].
Zhang T
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 May; 19(5):261-2. PubMed ID: 11783236
[No Abstract] [Full Text] [Related]
2. [Advances in the study on antineoplastic action of realgar].
Pan B; Xu L; Yang X
Zhong Yao Cai; 2004 Mar; 27(3):226-9. PubMed ID: 15346589
[No Abstract] [Full Text] [Related]
3. Treatment of acute promyelocytic leukemia with arsenic trioxide.
Tamm I; Paternostro G; Zapata JM
N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
[No Abstract] [Full Text] [Related]
4. Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Kizaki M; Muto A; Kinjo K; Ueno H; Ikeda Y
J Natl Cancer Inst; 1998 Dec; 90(24):1906-7. PubMed ID: 9862629
[No Abstract] [Full Text] [Related]
5. [Relationship of arsenic trioxide and tumor cell apoptosis].
Song J; Zhang DS
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Aug; 23(8):635-8. PubMed ID: 14503071
[No Abstract] [Full Text] [Related]
6. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
7. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
[No Abstract] [Full Text] [Related]
8. Co-biomodulation with arsenic trioxide in multiple myeloma.
Gallagher RE
Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
[No Abstract] [Full Text] [Related]
9. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
10. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
[No Abstract] [Full Text] [Related]
11. Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Chen GQ; Peng ZG; Liu W; Song LP; Jiang Y; Huang Y; Zhao Q
Sheng Li Xue Bao; 2006 Feb; 58(1):5-13. PubMed ID: 16489397
[TBL] [Abstract][Full Text] [Related]
12. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
13. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Matsui W; Smith BD; Vala M; Beal N; Huff CA; Diehl LF; Jones RJ
Br J Haematol; 2005 Mar; 128(6):853-62. PubMed ID: 15755292
[TBL] [Abstract][Full Text] [Related]
14. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
[No Abstract] [Full Text] [Related]
15. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
16. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
17. [A review of the research on malignant hemopathies treated with arsenium-containing Chinese drugs].
Chen SY; Li XM; Liu SX
Zhongguo Zhong Yao Za Zhi; 2000 Aug; 25(8):454-7, 473. PubMed ID: 12515204
[No Abstract] [Full Text] [Related]
18. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Yan J; Chen X; Shao J
Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
[No Abstract] [Full Text] [Related]
19. [Management of relapsed acute promyelocytic leukemia].
Emi N
Nihon Rinsho; 2012 Apr; 70 Suppl 2():420-4. PubMed ID: 23133993
[No Abstract] [Full Text] [Related]
20. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Powell BL
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
